Huntsman stock surges 63% after Fair Value spotted opportunity

Huntsman delivered a 62.68% return in just over five months after InvestingPro flagged it as undervalued (entry $8.12 on 10/11/25; InvestingPro FV then $12.01), peaking at $13.21. As of 3/29/26 the stock trades at $12.66 with InvestingPro’s updated fair value of $14.99 (estimated 13.5% upside). Company fundamentals show revenue around $5.68B (down from $5.78B), EBITDA down to $264M (from $310M) while EPS improved to -$1.65; headwinds include Fitch and S&P credit downgrades, a Q4 earnings miss and a Rotterdam outage, but management changes and a maintained dividend supported the recovery.

Analysis

HUN’s rebound is less about a one-off valuation gap and more about a regime shift in how the market prices mid-cycle specialty chemical players: investors are rewarding demonstrable cash-flow recovery and visible operational leverage over headline EPS volatility. That helps downstream formulators (coatings, adhesives, automotive suppliers) who gain more predictable input pricing and supply reliability; conversely, commodity-centric producers lacking specialty exposure will likely lag as capital reflows to higher-margin niches.

Near-term catalysts that will move the tape are operational continuity (plant reliability disclosures) and credit-market signals (spread compression or further rating actions); both operate on a weeks-to-months cadence and can amplify moves by changing funding costs and risk premia. Longer-term outcomes hinge on structural capacity rebalancing and M&A — if management uses any breathing room to deleverage and pursue tuck-ins, multiple expansion could be durable over 12–24 months, but persistent raw-material tailwinds reversing would re-test the thesis.

The primary tail risks are binary operational setbacks and a repricing of credit that forces cash-conservation measures (capex cuts, suspended distributions) within a single reporting cycle — these are fast-acting and can wipe out equity gains even if fundamentals recover later. Secondary risks include sector-wide margin compression from a renewed commodity oversupply or a demand shock in key end-markets (construction, autos), which would take quarters to manifest but compress valuations materially.

The consensus underweights the optionality embedded in idled specialty assets and management’s ability to convert fixed-cost recovery into free cash flow; equally, some investors may be under-pricing credit risk improvement as a multiplier for equity. That divergence creates a multi-instrument opportunity set: pure equity for upside capture, credit for yield and convexity to refinancing, and options to express asymmetric views with defined downside.

Key Decisions for Investors

• Directional equity: Initiate a 2–3% NAV long position in HUN (ticker: HUN) sized to tolerate a 12–15% drawdown; target 30–40% upside over 9–12 months if operational cadence and credit spreads improve. Place a hard stop at -18% or scale out if the stock rallies +20% in 3 months.
• Paired trade to isolate specialty outperformance: Long HUN (+2% NAV) / Short LYB or DOW (−1.5% NAV) to hedge commodity exposure; expect alpha to emerge in 6–12 months as specialty margin recovery outpaces commodity cyclicals. Rebalance if pair spread moves >25% versus base.
• Options asymmetric: Buy a 9–12 month HUN call spread (buy a near-ATM call, sell an out-of-the-money call ~25–35% higher) size to risk 0.75–1% NAV — this caps cost while keeping meaningful upside (2–4x payoff if thesis executes). Add a small protective put (3–6% NAV) as tail insurance if credit spreads widen.
• Credit/cash alternative: Evaluate senior unsecured HUN bonds trading at >400bp spread to investment-grade peers; initiate a buy at attractive yields with a 1–2 year horizon targeting spread compression and 8–12% IRR, but limit to 3% portfolio exposure given event-risk. Use bond purchase or CDS long protection as a hedge if concerned about short-term idiosyncratic risk.